These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 28057522)

  • 1. Nanomedicines for dysfunctional macrophage-associated diseases.
    He H; Ghosh S; Yang H
    J Control Release; 2017 Feb; 247():106-126. PubMed ID: 28057522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applying nanomedicine in maladaptive inflammation and angiogenesis.
    Alaarg A; Pérez-Medina C; Metselaar JM; Nahrendorf M; Fayad ZA; Storm G; Mulder WJM
    Adv Drug Deliv Rev; 2017 Sep; 119():143-158. PubMed ID: 28506745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine delivers promising treatments for rheumatoid arthritis.
    Prasad LK; O'Mary H; Cui Z
    Nanomedicine (Lond); 2015; 10(13):2063-74. PubMed ID: 26084368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases.
    Patel SK; Janjic JM
    Theranostics; 2015; 5(2):150-72. PubMed ID: 25553105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient Targeting of Adipose Tissue Macrophages in Obesity with Polysaccharide Nanocarriers.
    Ma L; Liu TW; Wallig MA; Dobrucki IT; Dobrucki LW; Nelson ER; Swanson KS; Smith AM
    ACS Nano; 2016 Jul; 10(7):6952-62. PubMed ID: 27281538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in nanomedicines for the treatment of rheumatoid arthritis.
    Wang Q; Sun X
    Biomater Sci; 2017 Jul; 5(8):1407-1420. PubMed ID: 28631779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
    Rubinstein I; Weinberg GL
    Nanomedicine; 2012 Sep; 8 Suppl 1():S77-82. PubMed ID: 22640912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats.
    Xie Z; Hao H; Tong C; Cheng Y; Liu J; Pang Y; Si Y; Guo Y; Zang L; Mu Y; Han W
    Stem Cells; 2016 Mar; 34(3):627-39. PubMed ID: 26523620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of macrophage in nanomedicine-based disease treatment.
    Song S; Xia H; Guo M; Wang S; Zhang S; Ma P; Jin Y
    Drug Deliv; 2021 Dec; 28(1):752-766. PubMed ID: 33860719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis.
    McCarthy JR; Korngold E; Weissleder R; Jaffer FA
    Small; 2010 Sep; 6(18):2041-9. PubMed ID: 20721949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicine for the prevention, treatment and imaging of atherosclerosis.
    Psarros C; Lee R; Margaritis M; Antoniades C
    Nanomedicine; 2012 Sep; 8 Suppl 1():S59-68. PubMed ID: 22640906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage-Targeted Therapeutics for Metabolic Disease.
    Peterson KR; Cottam MA; Kennedy AJ; Hasty AH
    Trends Pharmacol Sci; 2018 Jun; 39(6):536-546. PubMed ID: 29628274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer.
    Ponzoni M; Pastorino F; Di Paolo D; Perri P; Brignole C
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29973487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent.
    Mohammadi A; Blesso CN; Barreto GE; Banach M; Majeed M; Sahebkar A
    J Nutr Biochem; 2019 Apr; 66():1-16. PubMed ID: 30660832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine therapies modulating Macrophage Dysfunction: a potential strategy to attenuate Cytokine Storms in severe infections.
    Liu J; Wan M; Lyon CJ; Hu TY
    Theranostics; 2020; 10(21):9591-9600. PubMed ID: 32863947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional diversity of macrophages in vascular biology and disease.
    Park I; Kassiteridi C; Monaco C
    Vascul Pharmacol; 2017 Dec; 99():13-22. PubMed ID: 29074468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The upcoming field of theranostic nanomedicine: an overview.
    Prabhu P; Patravale V
    J Biomed Nanotechnol; 2012 Dec; 8(6):859-82. PubMed ID: 23029995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicines for kidney diseases.
    Williams RM; Jaimes EA; Heller DA
    Kidney Int; 2016 Oct; 90(4):740-5. PubMed ID: 27292222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
    Muthu MS; Singh S
    Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.